ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Merus NV

Merus NV (2GH)

42.00
0.80
(1.94%)
Closed 06 January 8:00AM
Realtime Data

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
42.00
Bid
41.40
Offer
42.40
Volume
160
41.60 Day's Range 42.00
25.20 52 Week Range 58.50
Previous Close
41.20
Open
41.60
Last Trade
10
@
41.6
Last Trade Time
Average Volume (3m)
189
Financial Volume
-
VWAP
-

2GH Latest News

Merus annonce le traitement du premier patient dans le cadre d’un essai de phase 2 portant sur le pétosemtamab dans le CCRm en 3e ligne et lignes ultérieures

Merus annonce le traitement du premier patient dans le cadre d’un essai de phase 2 portant sur le pétosemtamab dans le CCRm en 3e ligne et lignes ultérieures UTRECHT, Pays-Bas et CAMBRIDGE...

Merus gibt Verabreichung von petosemtamab an ersten Patienten in Phase-II-Studie bei 3L+ mCRC bekannt

Merus gibt Verabreichung von petosemtamab an ersten Patienten in Phase-II-Studie bei 3L+ mCRC bekannt UTRECHT, Niederlande und CAMBRIDGE, Massachusetts, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Merus...

Merus announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 3L+ mCRC

Merus announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 3L+ mCRC UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a...

Les données intermédiaires de Merus portant sur le pétosemtamab continuent de démontrer une activité cliniquement significative dans le traitement de 2e ligne et lignes ultérieures du CETC r/m

Les données intermédiaires de Merus portant sur le pétosemtamab continuent de démontrer une activité cliniquement significative dans le traitement de 2e ligne et lignes ultérieures du CETC r/m...

Zwischenergebnisse der Monotherapie mit Petosemtamab von Merus zeigen weiterhin klinisch signifikante Aktivität bei 2L+ r/m HNSCC

Zwischenergebnisse der Monotherapie mit Petosemtamab von Merus zeigen weiterhin klinisch signifikante Aktivität bei 2L+ r/m HNSCC Studie mit Petosemtamab in Kombination mit Pembrolizumab bei 1L...

Merus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC

Merus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC Petosemtamab in combination with pembrolizumab in 1L r/m PD-L1 expressing...

Merus annonce l’autorisation par la FDA de BIZENGRI® (zénocutuzumab-zbco) dans le traitement de l’adénocarcinome pancréatique NRG1+ et du cancer du poumon non à petites cellules (CPNPC) NRG1+, en fonction des données de sécurité et d’efficaci

Merus annonce l’autorisation par la FDA de BIZENGRI® (zénocutuzumab-zbco) dans le traitement de l’adénocarcinome pancréatique NRG1+ et du cancer du poumon non à petites cellules (CPNPC) NRG1+, en...

Merus gibt FDA-Zulassung von BIZENGRI® (Zenocutuzumab-zbco) für NRG1+-Adenokarzinome der Bauchspeicheldrüse und NRG1+-nicht-kleinzelligen Lungenkrebs (NSCLC) auf der Grundlage von Sicherheits- und Wirksamkeitsdaten aus der eNRGy-Studie bekannt

Merus gibt FDA-Zulassung von BIZENGRI® (Zenocutuzumab-zbco) für NRG1+-Adenokarzinome der Bauchspeicheldrüse und NRG1+-nicht-kleinzelligen Lungenkrebs (NSCLC) auf der Grundlage von Sicherheits- und...

Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy Study

Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy...

Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer

Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 02...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.2000010.47847130331341.7999994239.79999910540.92088525DE
4-0.799999-1.8691565857342.79999942.79999939.627940.99802788DE
12-6.6-13.580246913648.651.539.618944.53140804DE
26-8-16505439.617746.25299896DE
5215.659.090909090926.458.525.218344.878113DE
15618.276.470588235323.858.51917441.90952181DE
26018.276.470588235323.858.51917441.90952181DE

2GH - Frequently Asked Questions (FAQ)

What is the current Merus NV share price?
The current share price of Merus NV is 42.00 €
What is the 1 year trading range for Merus NV share price?
Merus NV has traded in the range of 25.20 € to 58.50 € during the past year

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
0S6Cerence Inc
18.972 €
(145.34%)
90.04k
CY9DMicrobot Medical Inc
2.11 €
(89.07%)
24.21k
RV0Torrent Gold Inc
0.138 €
(73.58%)
1.23k
7CCCheckCap Ltd
1.76 €
(55.75%)
6.55k
34Q0Quantum eMotion Inc
0.985 €
(53.91%)
1.62M
FASFastenal Co
9.7358 €
(-85.95%)
2.13k
1UR1Bee Vectoring Technologies International Inc
0.003 €
(-45.45%)
300.18k
B4T0CuFe Ltd
0.0045 €
(-25.00%)
1
H5EHelma Eigenheimbau Ag
0.0766 €
(-23.40%)
751
2WOWide Open Agriculture Ltd
0.005 €
(-23.08%)
50k
PF8European Lithium Limited
0.0264 €
(8.20%)
5.76M
3CPXiaomi Corporation
4.597 €
(7.34%)
3.95M
D7GNel ASA
0.247 €
(2.66%)
2.33M
J9AVERSES AI Inc
1.352 €
(0.00%)
1.67M
34Q0Quantum eMotion Inc
0.985 €
(53.91%)
1.62M

Discussion

View Full Feed
Koog Koog 5 minutes ago
Yep, that airport is a trip!

My Dad worked for Virginia Gas and managed the Covington office. Got promoted to the Staunton office and that's where I grew up. Jeebus, a long time ago.
HGilS HGilS 6 minutes ago
The way I read it through logic is that we do have an api provider that no one else is using and it was approved by the dea.

The api provider was the thing that was holding the Vyvanse approval.

When Vyvanse was approved then launched, it means the api provider was a
ELTP
ap17 ap17 7 minutes ago
YUP!! nothing but EPIC misses. Nutin.🏦🏦🚅🚅
XRPUSD
mrMadMax mrMadMax 8 minutes ago
🤡"But what are you rambling about? Do you keep smoking even on Sundays? Same BS .....Why not go do your job at the circus🤡? It would be better for you and for everyone than reading this street BS nonsense."🤡
ATMH
meidiot meidiot 8 minutes ago
I have tried to inform all posters for years that GMPR is not a great investment.
MR.JAMES C VOWLER IS A LIAR
GMPR
StonkMaster StonkMaster 9 minutes ago
You'd have to think (hope) we're worth more than 1.3-1.4B upon UK approval - maybe after NICE appraisal.
NWBO
real777mellon real777mellon 9 minutes ago
Are you literally attacking me and calling me crazy for sharing my stake in a very misunderstood stock and not widely understood 2008 fallout. Listen to Tucker's guest then. Targeted yes. It was Targeted.

Don't disrespect me or Bob or anyone. You're not making me feel like I am using
LEHNQ
EdibleZone EdibleZone 10 minutes ago
Vern did buy a lot of shares at $3.80 and I don't think he would have unless he believed things would work out. Beyond that I don't know, I agree they could do a lot better on the social media front. There have been a lot of delays, but I think that's typical for a small company that needs more capi
LCTC
ChannelTrader ChannelTrader 10 minutes ago
Cutting a boot off a tire, no brake work is required...whew.

https://www.youtube.com/shorts/cb8kA3uQfbY
oldstocks oldstocks 11 minutes ago
Golf, i know how you feel but please private message me when you got a great idea how to supplement our losses while holding AFFU

I need to make up just as much as you i think and feel
AFFU
real777mellon real777mellon 11 minutes ago
I'm disappointed I came back here happy and flattered that anyone would want to email anyone here my X post.

I have never had issues here.

If you want to bully me over being "political" - I won't come back.

But if you're like those $FNMA admins - your "po
FNMA
Nelson2 Nelson2 12 minutes ago
Leading credence to IPO/Spinoff?

GLTU
BB
Monroe1 Monroe1 12 minutes ago
So you are not interested in facts? What you call conspiracy theories is a hasty generalization that is not based in fact.
BIXT
Clark6290 Clark6290 12 minutes ago
Bad link
FNMA
RickNagra RickNagra 13 minutes ago
https://x.com/ricknagra/status/1876074015389020414?s=46&t=xLP2LlWgJrEMUZZ7Fum-nA
FNMA
22rover 22rover 13 minutes ago
Found this on the sidechannel website. In the company’s estimation, Enclave is the #1 competitor to Illumio, while Cisco ranks second and VMware third. That's impressive, to say the least, when you consider that privately-held Illumio has a current valuation in the billions. It’s analogou
SDCH
Acme Investments Acme Investments 13 minutes ago
You give a rough outline for business purposes!! Since you never ever even sniffed anything better than the fry rack or something that requires critical thinking you don't get it!! Many other things are happening behind the scenes!! Just like you looked up and had to read he gained custody while you
BCAP
SupernovaAstronaut88 SupernovaAstronaut88 14 minutes ago
(starting from the 20th ?)

From Monday, January 20, 2025
Added 100 days
Result: Wednesday, April 30, 2025
https://www.timeanddate.com/date/dateadded.html
FNMA
BeachBum BeachBum 14 minutes ago
You’re gonna be a millionaire
AHRO
MartinLutherKing MartinLutherKing 15 minutes ago
FDA Fast -Track status is possible https://financialpost.com/globe-newswire/transcode-therapeutics-announces-orphan-drug-designation-status-for-ttx-mc138-for-treatment-of-pancreatic-cancer
Monroe1 Monroe1 15 minutes ago
https://www.statista.com/statistics/1318652/covid-vaccine-lawsuits-industry/
PFE
INEEDMONEY INEEDMONEY 16 minutes ago
Oil! Trump in office ! This at .0001 ???? Why
PDGO

Your Recent History

Delayed Upgrade Clock